[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-121532-en":3,"doc-seo-121532-105":30,"detail-sidebar-cat-0-en-105":91},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"doc_content":15,"file_id":16,"file_url":17,"file_type":18,"file_size":19,"view_count":20,"is_deleted":4,"is_public":20,"is_downloadable":20,"audit_status":20,"page_count":21,"language":22,"language_code":23,"site_id":24,"html_lang":23,"table_of_contents":25,"faqs":26,"seo_title":27,"seo_description":14,"update_tm":28,"read_time":29},121532,687197207919,"Theodora","https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552",7,"Healthcare","Artificial intelligence for intelligent care - How machine learning algorithms can enhance the personalised treatment of patients with haemophilia A","Artificial intelligence for intelligent care explores how machine learning algorithms can support more personalized treatment for patients with haemophilia A. The thesis contextualizes haemophilia A as an X-linked bleeding disorder with severity defined by residual factor activity and associated bleeding risks, and traces the evolution from factor replacement therapies to recombinant products and newer options such as extended half-life formulations and non-factor treatments like emicizumab. The work frames clinical decision support through individualized data to improve outcomes and quality of life.","UvA-DARE (Digital Academic Repository)  \nArtificial intelligence for intelligent care  \nHow machine learning algorithms can enhance the personalised treatment of patients with haemophilia A  \nJanssen, A.  \nPublication date  \n2025  \nLink to publication  \nCitation for published version (APA):  \nJanssen, A. (2025) . Artificial intelligence for intelligent care: How machine learning algorithms can enhance the personalised treatment of patients with haemophilia A. [Thesis, fully internal, Universiteit van Amsterdam] .  \nGeneral rights  \nIt is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons) .  \nDisclaimer/Complaints regulations  \nIf you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: [https://uba.uva.nl/en/contact](https://uba.uva.nl/en/contact), or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.  \nUvA-DARE is a service provided by the library of the University of Amsterdam ( [http](https://dare. uva. nl)[s](https://dare. uva. nl)[://dare. uva. nl](https://dare. uva. nl))  \nDownload date:28 May 2025  \nGENERAL INTRODUCTION AND THESIS OUTLINE  \n1.1 haemophilia a  \n1.1.1 Background  \nBleeding disorders are rare conditions that are caused by a deficiency or qualitative defect of platelets or coagulation factors. These disorders involve a disruption in the process of coagulation, known as haemostasis, and can be differentiated into primary or secondary haemostatic disorders, fibrinolytic disorders, and bleeding disorders of unknown cause (where the precise aetiology has not (yet) been deciphered) . The most well-known bleeding disorders are haemophilia A (deficiency of factor VIII; FVIII), haemophilia B (deficiency in factor IX; FIX), and von Willebrand disease (deficiency of von Willebrand factor; VWF) . Amongst these three, von Willebrand disease is the most common with a prevalence rate of 1 per 100-1,000 individuals, compared to roughly 13 and 3 per 100,000 males for haemophilia A and B, respectively [1, 2] .  \nPatients with haemophilia A have impaired haemostasis, resulting in an elevated risk of (spontaneous) bleeding. Haemophilia A is X-linked, meaning that it almost exclusively affects males. The severity of the disorder is characterised in terms of the residual endogenous factor activity level, which is measured in international units (IU) using one stage and chromogenic clotting assays. Patients with mild haemophilia A have endogenous FVIII activity levels of around 5-40 IU/dL, moderate patients have levels between 1-5 IU/dL, and patients with less than 1 IU/dL are classified as having severe haemophilia A. Without adequate treatment, haemophilia A patients present with frequent (spontaneous) bleeding typically in joints and muscles leading to arthropathy, and have an elevated risk of life threatening bleeding events such as gastrointestinal and intracranial bleeding. In general, most moderate and mild haemophilia A patients have a milder bleeding phenotype with bleeding usually occurring following (minor) trauma or dental and other medical procedures.  \nIn this thesis, we focus mainly on data collected from severe and moderate haemophilia A patients with a more severe bleeding phe-  \n1  \nHaemostasis involves the process of forming a clot atthe site of bloodvessel damage to stop bleeding.  \nWomen have two copies of the X chromosome. Although a deficiency in both F8 genes is unlikely, haemophilia carriers can still present with low FVIII levels and elevated bleeding","cbCain7s4Djpw0W5","https://ap.wps.com/l/cbCain7s4Djpw0W5","pdf",705039,1,24,"English","en",105,"# General Introduction and Thesis Outline\n## Haemophilia A\n### Background\n## Evolving Treatment of Haemophilia A","[{\"question\":\"What does the thesis focus on regarding haemophilia A treatment?\",\"answer\":\"The thesis focuses on how machine learning algorithms can enhance personalised treatment for patients with haemophilia A, especially those with more severe disease patterns requiring regular therapy.\"},{\"question\":\"How is haemophilia A severity characterized in the thesis?\",\"answer\":\"Severity is characterized by residual endogenous factor activity level measured in international units (IU) using one-stage and chromogenic clotting assays, with thresholds distinguishing mild, moderate, and severe haemophilia A.\"},{\"question\":\"How has treatment for haemophilia A evolved, according to the introduction?\",\"answer\":\"Treatment evolved from whole blood/plasma/cryoprecipitate approaches to FVIII concentrates, then to recombinant FVIII and newer advances including extended half-life concepts and non-factor replacement options such as emicizumab.\"}]","Artificial intelligence for intelligent care - How machine learning algorithms can enhance the personalised treatment of patients with haemophilia A | PDF",1785736117,60,{"code":4,"msg":31,"data":32},"ok",{"site_id":24,"language":23,"slug":33,"title":13,"keywords":34,"description":14,"schema_data":35,"social_meta":86,"head_meta":88,"extra_data":90,"updated_unix":28},"artificial-intelligence-for-intelligent-care-how-machine-learning-algorithms-can-enhance-the-personalised-treatment-of-patients-with-haemophilia-a","",{"@graph":36,"@context":85},[37,54,68],{"@type":38,"itemListElement":39},"BreadcrumbList",[40,44,48,51],{"item":41,"name":42,"@type":43,"position":20},"https://docshare.wps.com","Home","ListItem",{"item":45,"name":46,"@type":43,"position":47},"https://docshare.wps.com/document/","Document",2,{"item":49,"name":12,"@type":43,"position":50},"https://docshare.wps.com/document/healthcare/",3,{"item":52,"name":13,"@type":43,"position":53},"https://docshare.wps.com/document/artificial-intelligence-for-intelligent-care-how-machine-learning-algorithms-can-enhance-the-personalised-treatment-of-patients-with-haemophilia-a/121532/",4,{"url":52,"name":13,"@type":55,"author":56,"headline":13,"publisher":58,"fileFormat":61,"inLanguage":23,"description":14,"dateModified":62,"datePublished":62,"encodingFormat":61,"isAccessibleForFree":63,"interactionStatistic":64},"DigitalDocument",{"name":9,"@type":57},"Person",{"url":41,"name":59,"@type":60},"DocShare","Organization","application/pdf","2026-08-03",true,{"@type":65,"interactionType":66,"userInteractionCount":20},"InteractionCounter",{"@type":67},"ViewAction",{"@type":69,"mainEntity":70},"FAQPage",[71,77,81],{"name":72,"@type":73,"acceptedAnswer":74},"What does the thesis focus on regarding haemophilia A treatment?","Question",{"text":75,"@type":76},"The thesis focuses on how machine learning algorithms can enhance personalised treatment for patients with haemophilia A, especially those with more severe disease patterns requiring regular therapy.","Answer",{"name":78,"@type":73,"acceptedAnswer":79},"How is haemophilia A severity characterized in the thesis?",{"text":80,"@type":76},"Severity is characterized by residual endogenous factor activity level measured in international units (IU) using one-stage and chromogenic clotting assays, with thresholds distinguishing mild, moderate, and severe haemophilia A.",{"name":82,"@type":73,"acceptedAnswer":83},"How has treatment for haemophilia A evolved, according to the introduction?",{"text":84,"@type":76},"Treatment evolved from whole blood/plasma/cryoprecipitate approaches to FVIII concentrates, then to recombinant FVIII and newer advances including extended half-life concepts and non-factor replacement options such as emicizumab.","https://schema.org",{"og:url":52,"og:type":87,"og:title":13,"og:site_name":59,"og:description":14},"article",{"robots":89,"canonical":52},"index,follow",{"doc_id":7,"site_id":24},{"code":4,"msg":5,"data":92},[93,97,101,105,109,114,117,122,127,130,134],{"id":20,"doc_module":4,"doc_module_name":46,"category_name":94,"show_sort_weight":95,"slug":96},"Story & Novel",90,"story-novel",{"id":47,"doc_module":4,"doc_module_name":46,"category_name":98,"show_sort_weight":99,"slug":100},"Literature",80,"literature",{"id":53,"doc_module":4,"doc_module_name":46,"category_name":102,"show_sort_weight":103,"slug":104},"Exam",70,"exam",{"id":106,"doc_module":4,"doc_module_name":46,"category_name":107,"show_sort_weight":29,"slug":108},5,"Comic","comic",{"id":110,"doc_module":4,"doc_module_name":46,"category_name":111,"show_sort_weight":112,"slug":113},6,"Technology",50,"technology",{"id":11,"doc_module":4,"doc_module_name":46,"category_name":12,"show_sort_weight":115,"slug":116},40,"healthcare",{"id":118,"doc_module":4,"doc_module_name":46,"category_name":119,"show_sort_weight":120,"slug":121},8,"Research & Report",30,"research-report",{"id":123,"doc_module":4,"doc_module_name":46,"category_name":124,"show_sort_weight":125,"slug":126},9,"Religion & Spirituality",20,"religion-spirituality",{"id":125,"doc_module":4,"doc_module_name":46,"category_name":128,"show_sort_weight":125,"slug":129},"World Cup","world-cup",{"id":131,"doc_module":4,"doc_module_name":46,"category_name":132,"show_sort_weight":131,"slug":133},10,"Lifestyle","lifestyle",{"id":135,"doc_module":4,"doc_module_name":46,"category_name":136,"show_sort_weight":106,"slug":137},19,"General","general"]